How have NAMSW shares performed in 2024?

NewAmsterdam Pharma's stock was trading at $3.13 at the start of the year. Since then, NAMSW shares have increased by 152.4% and is now trading at $7.8999. View the best growth stocks for 2024 here .

Who are NewAmsterdam Pharma's major shareholders?

NewAmsterdam Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Affinity Asset Advisors LLC (0.00%).

How do I buy shares of NewAmsterdam Pharma?

Shares of NAMSW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NAMSW

NewAmsterdam Pharma (NAMSW) Stock Price, News & Analysis

→ The only AI company to buy (From Porter & Company) (Ad)

Free NAMSW Stock Alerts

$7.90

-1.66 (-17.36%)

(As of 05/31/2024 ET)

Compare

Today's Range: $7.55
▼
$8.20
50-Day Range: $7.90
▼
$12.09
52-Week Range: $0.99
▼
$14.67

Volume: 2,682 shs
Average Volume: 14,084 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Ownership SEC Filings Short Interest Trends

Get NewAmsterdam Pharma alerts:

Ad Porter & Company

This military-backed stock “owns” AI market

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NAMSW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NAMSW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive NAMSW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:NAMSW
CUSIP: N/A
CIK: 1936258
Web: www.newamsterdampharma.com
Phone: 31 35 206 2971
Fax: N/A
Employees: 29
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $6.86 million
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Michael Harvey Davidson FACC (Age 68)
Facp., M.D., CEO, President, Executive Board Member & Director
Comp: $882k
Dr. Johannes Jacob Pieter Kastelein FESC (Age 70)
M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director
Comp: $677.76k
Mr. Mayur Amrat Somaiya (Age 51)
Chief Financial Officer
Comp: $130.58k
Ms. Juliette Audet M.B.A. (Age 37)
M.Sc., Chief Business Officer
Comp: $45.62k
Mr. Douglas F. Kling (Age 51)
Chief Operating Officer
Mr. Jim Jacobson
Chief Legal Officer & Secretary
Dr. Marc Ditmarsch M.D. (Age 57)
Chief Development Officer
Dr. Sheng Cui Ph.D.
VP & Head of Chemistry Manufacturing and Controls (CMC)
Ms. Annie Neild
VP & Head of Regulatory Affairs
Mr. William Jones Jr. (Age 60)
M.B.A., Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

Affinity Asset Advisors LLC
Bought 65,599 shares on 5/15/2024
Ownership: 0.000%

View All Institutional Transactions

NAMSW Stock Analysis - Frequently Asked Questions

How have NAMSW shares performed in 2024?: NewAmsterdam Pharma's stock was trading at $3.13 at the start of the year. Since then, NAMSW shares have increased by 152.4% and is now trading at $7.8999.
View the best growth stocks for 2024 here.
Who are NewAmsterdam Pharma's major shareholders?: NewAmsterdam Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Affinity Asset Advisors LLC (0.00%).
How do I buy shares of NewAmsterdam Pharma?: Shares of NAMSW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NAMSW) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial